DEERFIELD, Ill., Nov. 9, 2021 /PRNewswire/ -- TerSera Therapeutics LLC announced today the presentation of patient-reported clinical and productivity outcomes data from their registry trial (RELAX) in patients with carcinoid syndrome diarrhea (CSD) receiving treatment with Xermelo (telotristat ethyl). The data were presented in virtual poster sessions during the North American Neuroendocrine Tumor Society's (NANETS) Multidisciplinary NET Medical Symposium on November 3-6, 2021.1
TerSera Therapeutics LLC announced today the online publication of the TELEPRO-II study in the Journal of Cancer Management and Research.1 The findings are from the largest, real-world study with Xermelo® (telotristat ethyl) and included 684 patients with carcinoid syndrome (CS).
Three years ago, Lexicon Pharmaceuticals was flying high following the FDA approval and commercial launch of its Xermelo drug, which treats carcinoid syndrome diarrhea
THE WOODLANDS, Texas, May 13, 2020 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today additional data on XERMELO’s® (telotristat ethyl) antiproliferative effects against cultured liposarcoma, colon cancer and cholangiocarcinoma cell lines that were published online in conjunction with the American Society of Clinical Oncology (ASCO) 2020 annual meeting (May 29 - June 2, 2020). XERMELO is approved for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy, but is not currently approved for any other use.
THE WOODLANDS, Texas, July 30, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results and provided a business update for the three months ended June 30, 2018.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that it will host its 2018 Research & Development (R&D) Day on Tuesday, April 10, 2018, from 8:30 a.m. to 11:30 a.m. EDT (7:30 a.m. to 10:30 a.m. CDT) in New York City. Members of Lexicon’s senior management team will provide an update to the investment community on the company’s commercial product, XERMELO®, and along with external opinion leaders, provide in-depth overviews of the company’s development portfolio, including sotagliflozin for the treatment of type 1 and type 2 diabetes, LX2761 for diabetes and LX9211 for neuropathic pain.
The U.S. Food and Drug Administration (FDA) has accepted Sanofi’s regulatory filing for Zynquista (sotagliflozin). The investigational oral treatment would be used in addition to insulin therapy to improve blood sugar control in adults with type 1 diabetes.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that new XERMELO® (telotristat ethyl) data from the randomized, double-blind, placebo-controlled Phase 3 TELESTAR (Telotristat Etiprate for Somatostatin Analog Not Adequately Controlled Carcinoid Syndrome) study were published in Clinical Therapeutics.
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), announced today that the European Commission has approved XERMELO® (telotristat ethyl) 250 mg as a first and only orally administered therapy for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog (SSA) therapy in adults inadequately controlled by SSA therapy. This approval allows for the marketing of XERMELO by Lexicon’s collaborator, Ipsen, in the above indication in all 28 member states of the European Union, Norway and Iceland. Carcinoid syndrome is a rare and debilitating condition that affects people with metastatic neuroendocrine tumors (mNETs). XERMELO targets the overproduction of serotonin inside mNET cells, providing a new treatment option for patients suffering from carcinoid syndrome diarrhea.